The Alpha Omega Trial investigated in patients who have had heart attack whether cardiovascular diseases can be prevented by low-dose supplementation of omega-3 fatty acids in margarines. Previous literature pointed into that direction.

We found that low-dose supplementation with the fish fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or the plant food-based alpha linolenic acid (ALA) did not reduce major cardiovascular events among patients who had a heart attack. (Read our main publication at NEJM.org). In high-risk subgroups of patients who did not use statins or patients who also had diabetes, the hypothesized effects were observed of the additional amounts of omega-3 fatty acids on cardiovascular events.

On this website you can read about the design, the population, the protocols and data handling, the findings as well as the publications of the study.

The Alpha Omega Trial was coordinated by Marianne Geleijnse, Daan Kromhout was the principal investigator.